Ikarian Capital, LLC Cyclacel Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.56 - $1.15 $154,000 - $316,250	275,000 New	275,000 $156,000
Q1 2022 May 13, 2022	BUY	$5.93 - $7.6 $31,541 - $40,424	5,319 Added 5.35%	104,741 $319,000
Q3 2021 Nov 15, 2021	SELL	$8.02 - $11.0 $4,635 - $6,358	-578 Reduced 0.58%	99,422 $524,000
Q2 2021 Aug 16, 2021	SELL	$7.59 - $10.48 $1.52 Million - $2.1 Million	-200,000 Reduced 66.67%	100,000 $593,000
Q1 2021 May 17, 2021	SELL	$6.86 - $9.24 $627,347 - $844,998	-91,450 Reduced 23.36%	300,000 $2.13 Million
Q4 2020 Feb 12, 2021	BUY	$5.0 - $7.5 $1.96 Million - $2.94 Million	391,450 New	391,450 $3.06 Million

Ticker CYCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,539,200
Market Cap $4.64M
Description
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combin...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.